XML 75 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Data (unaudited) (Tables)
12 Months Ended
Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information [Table Text Block]

The following table summarizes the unaudited quarterly financial data for the last two fiscal years.

         
  2012
     First
Quarter
  Second
Quarter
  Third
Quarter
  Fourth
Quarter
  Total
Licensing revenue   $ 758,754     $ 758,755     $ 523,191     $ 405,405     $ 2,446,105  
Costs and expenses:                                             
Research and development     3,059,585       5,018,029       3,318,310       4,786,640       16,182,564  
General and administrative     1,059,202       943,857       991,062       2,183,008       5,177,129  
Total costs and expenses     4,118,787       5,961,886       4,309,372       6,969,648       21,359,693  
Other income (expense):                                             
Revaluation of warrants     677,907       301,568       (1,417,690 )      (24,187,383 )      (24,625,598 ) 
Foreign currency loss on liquidation           (191,733 )                  (191,733 ) 
Other income, net     2,434       7,308       16,883       61,223       87,848  
       680,341       117,143       (1,400,807 )      (24,126,160 )      (24,729,483 ) 
Net loss     (2,679,692 )      (5,085,988 )      (5,186,988 )      (30,690,403 )    $ (43,643,071 ) 
Dividends on preferred stock, not declared     (750,000 )      (750,000 )      (1,000,000 )      (130,435 )       
Net loss attibutable to common stockholders   $ (3,429,692 )    $ (5,835,988 )    $ (6,186,988 )    $ (30,820,838 )       
Net loss per common share-basic and diluted   $ (1.03 )    $ (1.75 )    $ (1.86 )    $ (2.02 )       
Weighted average shares outstanding, basic and diluted     3,329,266       3,329,266       3,329,266       15,223,010           

         
  2011
     First
Quarter
  Second
Quarter
  Third
Quarter
  Fourth
Quarter
  Total
Licensing revenue   $     $ 405,405     $ 640,972     $ 758,753     $ 1,805,130  
Costs and expenses:                                             
Research and development     2,229,545       2,521,268       2,512,248       4,163,094       11,426,155  
General and administrative     1,125,748       894,248       1,154,090       1,035,343       4,209,429  
Total costs and expenses     3,355,293       3,415,516       3,666,338       5,198,437       15,635,584  
Other income (expense):                                             
Revaluation of warrants     21,718       72,487       174,338       776,283       1,044,826  
Other income, net     665       19,618       10,098       17,593       47,974  
       22,383       92,105       184,436       793,876       1,092,800  
Net loss     (3,332,910 )      (2,918,006 )      (2,840,930 )      (3,645,808 )    $ (12,737,654 ) 
Dividends on preferred stock, not declared     (750,000 )      (750,000 )      (750,000 )      (750,000 )       
Net loss attibutable to common stockholders   $ (4,082,910 )    $ (3,668,006 )    $ (3,590,930 )    $ (4,395,808 )       
Net loss per common share-basic and diluted   $ (1.23 )    $ (1.10 )    $ (1.08 )    $ (1.32 )       
Weighted average shares outstanding, basic and diluted     3,329,266       3,329,266       3,329,266       3,329,266